Sort by
Keyphrases
Colorectal Cancer
100%
Bcl-xL
100%
Combination Treatment
100%
Wnt Signaling
100%
Targeted Treatment
100%
Novel Combinations
100%
CRISPR Interference (CRISPRi)
100%
ABT-263
83%
Colorectal Cancer Patients
66%
KRAS mutation
66%
Single Guide RNA (sgRNA)
50%
BRAF mutation
50%
Catenin
33%
Myeloid Cell leukemia-1 (Mcl-1)
33%
MiRNA Target
33%
Bcl-2 Family
33%
Synergistic Effect
16%
Negative Regulator
16%
Resistant Cells
16%
Positive Regulator
16%
Induced Cell Death
16%
Pharmacological Inhibitors
16%
Short Hairpin RNA (shRNA)
16%
Transcriptional Repression
16%
Therapeutic Potential
16%
Anti-apoptotic Proteins
16%
Anti-apoptotic
16%
Pro-apoptotic
16%
Patient Subgroups
16%
Therapeutic Target
16%
Worse Prognosis
16%
Metastatic Colorectal Cancer (mCRC)
16%
Systemic Chemotherapy
16%
Expression Ratio
16%
Gain-of-function mutation
16%
Family Gene
16%
Targeted Agents
16%
Combination Treatment Strategy
16%
Patient-derived Xenograft
16%
Functional Inhibition
16%
Recurrent Colorectal Cancer
16%
Targeted Combination
16%
Anti-EGFR Therapy
16%
CRISPR-Cas9 Screen
16%
Medicine and Dentistry
Colorectal Carcinoma
100%
Clustered Regularly Interspaced Short Palindromic Repeat
100%
Guide RNA
50%
Antiapoptotic
33%
Catenin
33%
Cell Death
16%
Gene Mutation
16%
Promoter Region
16%
Cell Line
16%
Multigene Family
16%
Xenograft
16%
Short Hairpin RNA
16%
Epidermal Growth Factor Receptor
16%
BRAF (Gene)
16%
Cas9
16%
Loss of Function Mutation
16%
Chemotherapy
16%
Biochemistry, Genetics and Molecular Biology
KRAS
100%
CRISPR
100%
Guide RNA
42%
Catenin
28%
MCL1
28%
Epidermal Growth Factor Receptor
14%
Gene Mutation
14%
Promoter Region
14%
Cell Death
14%
Multigene Family
14%
Genetics
14%
Small Hairpin RNA
14%
Loss of Function Mutation
14%
CRISPR/Cas9
14%
BRAF (Gene)
14%
Pharmacology, Toxicology and Pharmaceutical Science
Colorectal Carcinoma
100%
Guide RNA
50%
Antiapoptotic
33%
Catenin
33%
Epidermal Growth Factor Receptor
16%
Short Hairpin RNA
16%
Chemotherapy
16%